CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Caribou Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.46−0.01 (-1.26%)
Close on Oct 19, 2026
- Market cap
- $46.86M
- P/E (TTM)
- –
- Dividend yield
- –
Caribou Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Caribou Biosciences | Industry median |
|---|---|---|
| Market Cap | $49.74M | $197.05M |
| Enterprise Value | -$64.06M | $106.56M |
| PS Ratio | 4.96 | 3.93 |
| PB Ratio | 0.51 | 2.14 |
| P/TBV Ratio | 0.51 | 2.46 |
Enterprise value
| Measure | Caribou Biosciences | Industry median |
|---|---|---|
| EV / Sales | -6.38 | 2.69 |
Income (trailing twelve months)
| Measure | Caribou Biosciences | Industry median |
|---|---|---|
| Revenue | $10.04M | $57.94M |
| Operating Income | -$109.47M | -$21.44M |
| Net Income | -$103.40M | -$22.46M |
| EBITDA | -$106.89M | -$16.91M |
| EPS (Diluted) | -$1.08 | -$0.83 |
Margins
| Measure | Caribou Biosciences | Industry median |
|---|---|---|
| Operating Margin | -1090.9% | -44.5% |
| Profit Margin | -1030.4% | -39.2% |
| EBITDA Margin | -1065.1% | -31.3% |
| FCF Margin | -954.2% | -8.85% |
Returns
| Measure | Caribou Biosciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -78.3% | -53.1% |
| Return on Assets (ROA) | -56.9% | -41.0% |
| Return on Capital Employed (ROCE) | -87.7% | -37.8% |
Growth
| Measure | Caribou Biosciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 10.0% | 6.01% |
| Revenue Growth (3Y CAGR) | -6.95% | 2.25% |
| Revenue Growth (5Y CAGR) | -2.03% | 6.42% |
Balance sheet
| Measure | Caribou Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $113.80M | $62.42M |
| Net Cash (Debt) | $113.80M | $15.68M |
| Net Cash Per Share | $1.06 | $0.65 |
| Equity (Book Value) | $98.10M | $48.79M |
| Book Value Per Share | $0.92 | $1.36 |
| Tangible Book Value | $98.10M | $23.06M |
| Working Capital | $98.62M | $75.77M |
Financial position
| Measure | Caribou Biosciences | Industry median |
|---|---|---|
| Current Ratio | 6.49 | 3.30 |
| Quick Ratio | 6.34 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Caribou Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$95.78M | -$12.35M |
| Capital Expenditures | $28.00K | -$1.06M |
| Free Cash Flow | -$95.75M | -$20.28M |
| FCF Per Share | -$0.89 | -$0.41 |
Efficiency
| Measure | Caribou Biosciences | Industry median |
|---|---|---|
| Asset Turnover | 0.06 | 0.38 |
| Revenue Per Employee | $103.45K | $398.96K |
| Profits Per Employee | -$1.07M | -$732.08K |
| Employee Count | 97 | 73 |
Dividends and yields
| Measure | Caribou Biosciences | Industry median |
|---|---|---|
| Earnings Yield | -207.9% | -21.2% |
| FCF Yield | -192.5% | -7.64% |
| Buyback Yield | -48.7% | -0.58% |
| Shareholder Yield | -48.7% | 0.00% |
Shares
| Measure | Caribou Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 107,208,000 | 59,128,900 |
| Shares Change (YoY) | 4.73% | 11.1% |
| Shares Change (QoQ) | 9.33% | 0.54% |
| Float | 101,141,000 | 48,744,500 |
| Shares Held by Insiders | 5.66% | 11.8% |
| Shares Held by Institutions | 45.5% | 59.4% |
Scores
| Measure | Caribou Biosciences | Industry median |
|---|---|---|
| Altman Z-Score | -7.30 | 0.10 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Caribou Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.